Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2023 | 2 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis.
J Neurol Neurosurg Psychiatry. 2023 Dec;94(12):1056-1063. doi: 10.1136/jnnp-2022-330463. Epub 2023 Jul 10.
J Neurol Neurosurg Psychiatry. 2023.
PMID: 37434321
Review.
The committee: (1) created a new definition of CFS/ME, which 'downgraded' the certainty of trial evidence; (2) omitted data from standard trial end points used to assess efficacy; (3) discounted trial data when assessing treatment harm in favour of lower quality surveys an …
The committee: (1) created a new definition of CFS/ME, which 'downgraded' the certainty of trial evidence; (2) omitted data from standard tr …
An optimal investment consumption model for retirees with no health insurance.
Dzupire N, Mutepuwa J.
Dzupire N, et al.
Heliyon. 2024 Apr 9;10(8):e29034. doi: 10.1016/j.heliyon.2024.e29034. eCollection 2024 Apr 30.
Heliyon. 2024.
PMID: 38638984
Free PMC article.
In our model, the stock price dynamics follow Geometric Brownian motion (GBM) and our goal was to optimize the expected discounted utility of consumption and terminal wealth whilst considering health expenses. ...In our numerical results it showed various effects of …
In our model, the stock price dynamics follow Geometric Brownian motion (GBM) and our goal was to optimize the expected discounted ut …
Item in Clipboard
The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program.
Bond AM, Dean EB, Desai SM.
Bond AM, et al.
Health Aff (Millwood). 2023 May;42(5):632-641. doi: 10.1377/hlthaff.2022.00812.
Health Aff (Millwood). 2023.
PMID: 37126754
Biosimilar drugs-lower-cost alternatives to expensive biologic drugs-have the potential to slow the growth of US drug spending. ...We investigated whether the 340B Drug Pricing Program, which offers eligible hospitals substantial discounts on drug purchases, inhibit …
Biosimilar drugs-lower-cost alternatives to expensive biologic drugs-have the potential to slow the growth of US drug spending. ...We …
Item in Clipboard
Cite
Cite